Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Gruppo Italiano Malattie EMatologiche dell'Adulto: Clinical Trials & FDA Approval Profile

Gruppo Italiano Malattie EMatologiche dell'Adulto (Global / Institutional) sponsors 21 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 12 active protocols (4 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)14.3%
Median Closed Enrollment vs National (145 pts)89 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Gruppo Italiano Malattie EMatologiche dell'Adulto
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)21
Active Pipeline (Recruiting Now)12 (4)
Completed vs Stopped Early3 / 3 (14.3%)
Median Closed Actual Enrollment89 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Gruppo Italiano Malattie EMatologiche dell'Adulto Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI